BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PlaCor, Inc. Announces Appointment of John Reinke as CEO


8/20/2007 8:52:58 AM

PLYMOUTH, Minn.--(BUSINESS WIRE)--PlaCor, Inc. announced today that John Reinke has been appointed Chief Executive Officer, effective September 4, 2007. William S. Haworth has been named Chief Technology Officer and will focus on the continued development of the Company's platelet reactivity testing technology.

Mr. Reinke was most recently a Senior Vice President for UnitedHealth Group in Minnetonka, Minnesota, responsible for leading innovation initiatives for service, operations, technology and new products. He is a leading expert in consumer-directed health (CDH) and helped United become a market leader in this arena by supporting new service models, new technologies and due diligence for related acquisitions, including the purchase of Definity Health. Mr. Reinke has 30 years of experience in health care, management consulting and financial services and has held positions in operations, sales and marketing, product development and finance.

PlaCor, Inc., based in Plymouth, Minnesota, is a privately-held corporation which is developing a simple, easy to use, proprietary, global, point-of-care test to measure platelet reactivity. Anti-platelet drugs, such as aspirin and Plavix®, are often prescribed by physicians to inhibit platelet reactivity as part of a regimen to reduce the occurrence and severity of heart attacks and strokes. The PlaCor test will be used initially to monitor anti-platelet therapy. The test is available for research purposes only and is currently the subject of a premarket notification review by the Food and Drug Administration pursuant to Section 510(k) of the Food, Drug and Cosmetic Act.

Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

Contact: PlaCor, Inc. Joseph Margarit, 763-398-6216 joem@placorinc.com

Source: PlaCor, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES